Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P ...

Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last ...

Hedge fund Starboard reveals Q2 strategy shifts: new stakes in TripAdvisor & iShares Russell 2000 ETF, boosted Salesforce & Pfizer holdings, trimmed ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...